Enanta Pharmaceuticals, Inc. reported a net loss of $19.5 million for its fiscal third quarter ended June 30, 2026, missing analyst expectations as revenue declined 21 percent year-over-year to $14.4 million. Despite the financial headwinds, the clinical-stage biotechnology company advanced its respiratory syncytial virus (RSV) pipeline by initiating dosing in the LOTUS Phase 2b pediatric trial and preparing for the registrational RESOLVE trial in high-risk adults. The company holds $211.5 million in cash and marketable securities, providing a runway into fiscal 2029.

The quarterly results reflect a net loss per diluted share of $(0.67), compared to $(0.85) in the same period of FY25. Total revenue fell from $18.3 million in Q3FY25 to $14.4 million in Q3FY26, primarily due to lower reported sales of AbbVie’s MAVYRET/MAVIRET regimen. Interest expense rose to $4.1 million from $1.6 million year-ago, linked to the royalty sale transaction with OMERS. Research and development expenses decreased to $22.1 million from $27.2 million, while general and administrative costs dropped to $9.5 million from $10.0 million.

Financial Performance Overview

The divergence between operational cost controls and declining royalty income underscores the transition phase for Enanta. While R&D spend was reduced through lower clinical trial expenses for RSV programs, the drop in top-line revenue widened the gap against analyst estimates. The company recorded interest and investment income of $1.9 million, down from $2.3 million in the prior year period, reflecting lower interest rates.

Clinical Pipeline Updates

Enanta’s virology portfolio remains focused on zelicapavir, an N-protein inhibitor for RSV. Dosing began in the LOTUS trial, which evaluates zelicapavir in approximately 150 hospitalized and non-hospitalized children aged 28 days to 36 months in Thailand. Topline data is expected in 2027. Additionally, the company announced plans to initiate RESOLVE, a registrational Phase 2b/3 trial in high-risk adults, in the fourth quarter of 2026. This follows an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Topline Phase 2b data from RESOLVE is also anticipated in 2027.

In immunology, Enanta is advancing EDP-978, a KIT inhibitor for chronic urticaria. The first participant was dosed in a Phase 1 trial, with topline data expected in Q4FY26. The company also plans to file an Investigational New Drug (IND) application for EPS-3903, a STAT6 inhibitor for atopic dermatitis, in the second half of 2026. Furthermore, Enanta expects to select an MRGPRX2 development candidate in H2 2026.

What the Numbers Show

The financial data reveals a strategic pivot where near-term profitability is sacrificed for long-term pipeline advancement. The 21 percent decline in revenue highlights the dependency on AbbVie’s HCV sales, which are naturally decaying. However, the reduction in R&D expenses suggests disciplined capital allocation as the company moves key candidates into later-stage trials. With $211.5 million in liquidity, Enanta is well-positioned to fund operations into fiscal 2029 without immediate dilution risk, allowing it to focus on delivering topline data from multiple high-value trials in the coming year.

Enanta Pharmaceuticals entered into an open market sale agreement with Jefferies, according to a Securities and Exchange Commission (SEC) filing. The agreement authorizes the company to offer and sell up to $75M of its common stock through Jefferies as the sales agent. This move provides Enanta with the flexibility to raise capital by issuing shares at market prices over time.

Agreement Details

Under the terms of the agreement, Jefferies will act as the sales agent for Enanta Pharmaceuticals. The company is not obligated to sell any specific amount of stock but has the discretion to offer shares up to the aggregate value of $75M. The actual timing and amount of any sales will be determined at Enanta's sole discretion.

Sales Mechanics

The common stock will be sold through various methods deemed permissible by applicable regulations, including transactions on the Nasdaq Stock Market or in negotiated transactions. The price per share will be based on prevailing market conditions at the time of each sale. Enanta intends to use the net proceeds from any such sales for general corporate purposes, which may include working capital, capital expenditures, or potential acquisitions.